UCB Showcases the Depth of its Immunology Research and Commitment to Patients at EULAR 2019


Brussels, Belgium – 7 June 2019

  • Three oral presentations on novel investigational molecule bimekizumab to show potential for improving disease activity and quality of life outcomes in patients with ankylosing spondylitis, and musculoskeletal and skin outcomes over 48 weeks in those with psoriatic arthritis
  • Multiple presentations will highlight the value of CIMZIA® (certolizumab pegol) in the treatment of axial spondyloarthritis, including new data from a 52-week placebo-controlled study on the benefit of early intervention for rapid and durable symptom control in patients with non-radiographic axial spondyloarthritis

Patient research demonstrating the need to educate and engage women with chronic inflammatory diseases about their disease state and family planning

Brussels, Belgium – 7 June 2019 – UCB, a global biopharmaceutical company, will present results from the clinical development program of the company’s key pipeline molecule, bimekizumab – a novel humanized monoclonal IgG1 antibody that is thought to potently and selectively neutralizes both IL-17A and IL-17F cytokines – and the company’s Fc-free anti-TNF treatment CIMZIA® (certolizumab pegol) at the Annual European Congress of Rheumatology (EULAR 2019), taking place in Madrid, June 12-15, 2019. These data underscore the company’s commitment to advancing rheumatology science in order to transform the lives of patients living with chronic inflammatory diseases.

“At EULAR 2019, we are proud to present these positive findings on our pipeline molecule bimekizumab, while other studies reinforce the value of CIMZIA in a range of patients who have specific treatment requirements, particularly those with axial spondyloarthritis. UCB is committed to serving as partners in care, supporting patients and rheumatologists dealing with challenging treatment situations and improving the clinical understanding of their needs. Our aim is to bring real world value to patients with significant unmet needs,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President, Immunology Patient Value Unit, UCB.

As part of the oral presentations, week 12 findings from a Phase 2b bimekizumab study demonstrating improvements in disease activity and patient-reported outcomes, such as pain, fatigue, function, morning stiffness, and quality of life (QoL) in patients with active ankylosing spondylitis (AS) will be presented. Results from a 48-week Phase 2b randomized study in patients with psoriatic arthritis (PsA) will also be presented, supporting bimekizumab’s long term efficacy and safety profile in this condition.2 A third presentation will provide further insight into the biology of IL-17A and IL-17F, supporting the value of dual neutralization of those cytokines as a targeted approach for suppression of inflammation.

CIMZIA data to be featured at EULAR 2019 include four new analyses from studies in patients with axial spondyloarthritis (axSpA). Important post-hoc results from the C-AXSPAND study will support the efficacy and safety of CIMZIA treatment in patients with non-radiographic axSpA, and show the benefit of early treatment. An interim analysis will be presented from C-OPTIMISE that demonstrated sustained remission during 48 weeks of CIMZIA treatment in patients with ankylosing spondylitis (AS) and non-radiographic axSpA. Additionally, a new analysis from the RAPID-axSpA study confirms that CIMZIA treatment in axSpA patients rapidly reduced active inflammation in the spine, which was sustained over 4 years and was associated with negligible increase in fatty lesions in the vertebral edges.

As part of UCB’s commitment to ongoing patient value, the company will present findings from a survey of women in Europe and Asia-Pacific demonstrating a need to educate and engage women with chronic inflammatory disease around family planning issues, to allow them to make informed decisions with their physicians around their care.

In addition to the 12 data presentations, UCB will be sponsoring a satellite symposium highlighting the challenges that women with axSpA and PsA face, and the important role of shared decision making between patients and healthcare professionals when considering treatment options.

Partner Content biedt organisaties toegang tot het netwerk van De Tijd. De Partner zijn verantwoordelijk voor de inhoud.

Gesponsorde inhoud